glp 1 for people without diabetes Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight and Cardiometabolic Parameters in Individuals With Obesity and Diabetes: A Systematic Review and Meta-Analysis More people with type 1
Description
Gastrointestinal symptomsincluding nausea, vomiting, dizziness and headachesare frequent, particularly during dose escalation
These coordinated adaptations enable therapeutic weight reduction
All were tracked for at least 5 years
however, this analysis was conducted in general obesity and diabetes populations, not IBD-specific cohorts, and its findings may not directly translate to patients with underlying intestinal inflammation (97)
This is where the expertise of a healthcare professional becomes invaluable
